Skip to main content

ERRATUM article

Front. Oncol., 28 March 2023
Sec. Hematologic Malignancies
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1190120

Erratum: Glutathione levels are associated with methotrexate resistance in acute lymphoblastic leukemia cell lines

This article is an erratum on:

  1. Glutathione levels are associated with methotrexate resistance in acute lymphoblastic leukemia cell lines

    1. Read original article
Frontiers Production Office* Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Glutathione levels are associated with methotrexate resistance in acute lymphoblastic leukemia cell lines

By Canevarolo RR, Melo CPS, Cury NM, Artico LL, Corrêa JR, Lau YT, Mariano SS, Sudalagunta PR, Brandalise SR, Zeri ACM, and Yunes JA (2022) . 12:1032336. doi: 10.3389/fonc.2022.1032336

Due to a production error, the given names, and surnames of the authors in the citation were changed to “Renatino Canevarolo R, Pereira de Souza Melo C, Moreno Cury N, Luiz Artico LL, Ronchi Corrêa J, Tonhasca Lau Y, Sousa Mariano S, Reddy Sudalagunta P, Regina Brandalise S, Carolina de Mattos Zeri A and Andrés Yunes J (2022) Glutathione levels are associated with methotrexate resistance in acute lymphoblastic leukemia cell lines. Front. Oncol. 12:1032336. doi: 10.3389/fonc.2022.1032336”. The correct citation is “Canevarolo RR, Melo CPS, Cury NM, Artic LL, Corrêa JR, Lau YT, Mariano SS, Sudalagunta PR, Brandalise SR, Zeri ACM, and Yunes JA (2022) Glutathione levels are associated with methotrexate resistance in acute lymphoblastic leukemia cell lines. Front. Oncol. 12:1032336. doi: 10.3389/fonc.2022.1032336”. The publisher apologizes for this mistake.

The original version of this article has been updated.

Keywords: acute lymphoblastic leukemia, methotrexate, glutathione, metabolomics, drug resistance, arsenic trioxide, thioredoxin reductase

Citation: Frontiers Production Office (2023) Erratum: Glutathione levels are associated with methotrexate resistance in acute lymphoblastic leukemia cell lines. Front. Oncol. 13:1190120. doi: 10.3389/fonc.2023.1190120

Received: 20 March 2023; Accepted: 20 March 2023;
Published: 28 March 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.